Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 4/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | PNP | P00491 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | KRAS | P01116 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535718 | 0.92 | HINT1 (0.58) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL23710670 | 0.89 | TAAR1 (0.58) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL780400 | 0.89 | TAAR1 (0.58) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL800400 | 0.89 | TAAR1 (0.58) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL23200376 | 0.89 | TAAR1 (0.58) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL23200375 | 0.89 | TAAR1 (0.58) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL7111072 | 0.89 | HINT1 (0.55) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL23710671 | 0.89 | TAAR1 (0.58) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL7541561 | 0.89 | TAAR1 (0.56) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL800874 | 0.89 | TAAR1 (0.58) | HINT1NT5ESTING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| EP-4661900-A1 | IMMUNE EFFECTOR CELLS STABLY AND TRANSIENTLY EXPRESSING NUCLEIC ACIDS | BIONTECH CELL & GENE THERAPIES GMBH (DE) | 2025-12-17 | — | — | EP | claimed |
| WO-2025132708-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF HUNTINGTON'S DISEASE | PROQR THERAPEUTICS II B.V. (NL) | 2025-06-26 | — | — | WO | claimed |
| WO-2025104239-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CLASSIC GALACTOSEMIA | PROQR THERAPEUTICS II B.V. (NL) | 2025-05-22 | — | — | WO | claimed |
| EP-4555086-A1 | OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF | ProQR Therapeutics II B.V. (NL) | 2025-05-21 | — | — | EP | claimed |
| CN-116514908-B | EGFR targeting polypeptide and application thereof in preparation of targeting drug delivery system for treating EGFR abnormal expression diseases | 四川大学华西医院 | 2025-05-16 | — | — | CN | claimed |
| CN-119907691-A | Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions and therapeutic uses | 厦门甘宝利生物医药有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-115591086-B | Method for manufacturing drug coated balloon and drug coated balloon | 北京先瑞达医疗科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-118512703-B | Medicine sacculus pipe | 北京海盛医疗器械有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119789859-A | Treatment of non-alcoholic fatty liver disease | 箭头药业股份有限公司 | 2025-04-08 | — | — | CN | claimed |
| US-20140147454-A1 | TERMINALLY MODIFIED RNA | MODERNA THERAPEUTICS, INC. (US) | 2014-05-29 | — | — | US | claimed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | claimed |
| US-20130266640-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2013-10-10 | — | — | US | claimed |
| US-20130259923-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | modeRNA Therapeutics (US) | 2013-10-03 | — | — | US | claimed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | claimed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | HINT1 440/4885NT5E 44/4885STING1 149/4885 |
| US-20130266640-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | HINT1 440/4885NT5E 44/4885STING1 149/4885 |
| US-20140147454-A1 | TERMINALLY MODIFIED RNA | RNGTT, NSUN3, RNMT | HINT1 2512/4885NT5E 234/4885STING1 660/4885 |
| US-20020177695-A1 | Nucleic acid probes and methods | NUDT1, NT5C3B, NT5C2 | HINT1 96/4885NT5E 9/4885STING1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.